Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships n/a; licensed from TRDF (up to $6.5M milestones per product, low-to-mid single-digit royalties); CFF funding obligations reduced to <1% of net sales
Indications
Alport syndrome with nonsense mutations (NMAS)(Phase 2)
Autosomal dominant polycystic kidney disease with nonsense mutations (nmADPKD)(Preclinical)
Catalysts
— Q3 2026
— mid-2027
— end of 2027
— 2027
— mid-2028
Status note Lead candidate; completed Phase 2a (n=3) in NMAS. Prior Phase 2 studies in CF and nephropathic cystinosis also completed; program focus shifted to kidney indications. Orphan designations: FDA (Alport syndrome), EU (ADPKD, Jul 2026).
ZKN-013
Phase 1 · ActiveModality: small molecule (oral ribosome modulating agent)
Partnerships Almirall, S.A.: exclusive global license (Mar 2024); $3M upfront + $3M development milestone received 2024; up to ~$470M additional milestones; tiered royalties. Almirall responsible for development/commercialization.
Indications
Recessive dystrophic epidermolysis bullosa (RDEB) with nonsense mutations(Phase 1)
Junctional epidermolysis bullosa (JEB) with nonsense mutations(Phase 1)
Status note Partnered program; Almirall conducting Phase 1 in healthy volunteers. Rights revert to Eloxx if Almirall terminates for convenience.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.